Occasionally analysts can be guilty of over complicating matters. Strip out the jargon however, and often even the most complex of businesses can be distilled into four simple questions. Are revenues growing faster than costs? Will this be maintained in the long run? Is management investing enough to stay ahead of the game? And finally, how much are the shares worth compared to the current price? For ClearStar - a tech-pioneer in the $4bn global job screening (60% H1 sales) and medical (MIS 40%) testing market - we unequivocally got the thumbs-up again from this morning’s very encouraging H1’18 results.
17 Sep 2018
Valuation raised due to accelerating growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Valuation raised due to accelerating growth
Occasionally analysts can be guilty of over complicating matters. Strip out the jargon however, and often even the most complex of businesses can be distilled into four simple questions. Are revenues growing faster than costs? Will this be maintained in the long run? Is management investing enough to stay ahead of the game? And finally, how much are the shares worth compared to the current price? For ClearStar - a tech-pioneer in the $4bn global job screening (60% H1 sales) and medical (MIS 40%) testing market - we unequivocally got the thumbs-up again from this morning’s very encouraging H1’18 results.